Silicon Photonics Momentum Builds, But Tower Semiconductor's Valuation Remains Rich

What happened

Tower Semiconductor is entering a growth phase driven by silicon photonics, with the Seeking Alpha article citing $1.3B in 2027 contracts and $290M in pre-payments as evidence of strong demand. Q2 2026 results showed revenue of $460M, up 23.7% YoY, with gross margin of 30% and normalized EPS of $0.88, beating expectations and highlighting operating leverage from the new segment. Management has set aggressive targets of $3.6B revenue and $1.2B net income by 2028, which require achieving 45% gross margin and 85% capacity utilization. The DeepValue master report currently rates the stock a HOLD, citing rich valuation at 42x P/E and 41x EV/EBITDA, along with risks from mature-node pricing pressure and execution on capacity expansions. While the silicon photonics opportunity is real and recent results are encouraging, the market already appears to be pricing in much of the growth, leaving limited margin of safety for investors.

Implication

Tower's silicon photonics segment is gaining traction with substantial contract wins and prepayments, which strengthens its long-term growth story and could justify a higher multiple if management's 2028 targets are met. However, the current stock price already embeds optimistic assumptions, trading at over 40x earnings, leaving little room for error in achieving the required gross margin and utilization improvements. Investors should monitor the ramp of ST's Agrate 300mm facility and the qualification of the Intel New Mexico corridor, as these are critical to meeting capacity and cost targets. Mature-node pricing pressure from Chinese competitors remains a structural headwind that could offset gains from new products. Overall, the risk/reward appears balanced, so we would not chase the stock at current levels but would reconsider on a pullback or on clearer evidence of margin expansion.

Thesis delta

The news provides concrete evidence of silicon photonics demand with signed contracts and prepayments, which strengthens the growth narrative and partly mitigates execution risk on that segment. However, the aggressive 2028 targets are not yet proven, and the stock's valuation remains elevated, so we maintain a HOLD rating but with a positive bias if gross margin and utilization targets are met.